| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (770kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-515345
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.51534
Zusammenfassung
Background: It is still incompletely understood why some patients with preformed donor-specific anti-HLA antibodies (DSA) have reduced kidney allograft survival secondary to antibody-mediated rejection (ABMR), whereas many DSA-positive patients have favorable long-term outcomes. Elevated levels of soluble CD30 (sCD30) have emerged as a promising biomarker indicating deleterious T-cell help in ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik